Literature DB >> 24095205

New drugs and targeted treatments in Hodgkin's lymphoma.

Mariano Provencio1, Antonio Sánchez2, Margarita Sánchez-Beato2.   

Abstract

New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin's lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bendamustine; Brentuximab vedotin; Deacetylase inhibitors; Hodgkin’s lymphoma; Lenalidomide; Target treatments; m-TOR inhibitors

Mesh：

Substances：

Year:  2013        PMID： 24095205     DOI： 10.1016/j.ctrv.2013.09.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  3 in total

Review 1.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

Review 2.  Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma.

Authors:  Barbara Jezersek Novakovic
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

3.  Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Authors:  Maurizio Musso; Giuseppe Messina; Nicola Di Renzo; Paolo Di Carlo; Umberto Vitolo; Renato Scalone; Gianpaolo Marcacci; Potito R Scalzulli; Tiziana Moscato; Rossella Matera; Alessandra Crescimanno; Stella Santarone; Enrico Orciuolo; Anxur Merenda; Vincenzo Pavone; Domenico Pastore; Daniela Donnarumma; Angelo M Carella; Chiara Ciochetto; Nicola Cascavilla; Anna Mele; Francesco Lanza; Massimo Di Nicola; Erminio Bonizzoni; Antonello Pinto
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.